Atherosclerosis Drugs Market Forecast 2024-2033: Growth Rate, Drivers, And Trends

The Atherosclerosis Drugs Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Atherosclerosis Drugs Market:

https://www.thebusinessresearchcompany.com/report/atherosclerosis-drugs-global-market-report

According to The Business Research Company’s Atherosclerosis Drugs Global Market Report 2024, The atherosclerosis drugs market size has grown steadily in recent years. It will grow from $48.72 billion in 2023 to $50.5 billion in 2024 at a compound annual growth rate (CAGR) of 3.6%. The growth in the historic period can be attributed to cholesterol management, blood pressure control, smoking cessation programs, research and development, diagnostic advancements.

The atherosclerosis drugs market size is expected to see steady growth in the next few years. It will grow to $57.03 billion in 2028 at a compound annual growth rate (CAGR) of 3.1%. The growth in the forecast period can be attributed to emerging therapies, precision medicine, immunotherapy and inflammation, innovations in lipid management, regulatory support. Major trends in the forecast period include biologic therapies, gene editing and gene therapy, combination therapies, personalized treatment approaches, telemedicine and remote monitoring.

The prevalence of cardiovascular diseases is expected to propel the growth of the atherosclerosis drug market going forward. Cardiovascular diseases refer to all the diseases that can affect the heart and blood vessels, and atherosclerosis refers to the buildup of fats, cholesterol, and other substances on the artery walls of a person. Atherosclerosis is a condition characterized by the buildup of plaque inside the arteries that causes cardiovascular diseases such as coronary heart disease and stroke. Atherosclerosis drugs are used to treat cardiovascular diseases by reducing the risk of complications and managing underlying conditions such as increased cholesterol levels and blood clot formation. For instance, in March 2022, according to a report published by The Office for National Statistics, a UK-based government department, between 2020 and 2021, 19,440 to 20,061 people died due to heart attacks. Further, in May 2023, the Centers for Disease Control and Prevention., a US-based national public health agency, reported that in the US, 1 in 20 adults aged 20 and older have cardiovascular diseases, and 695,000 people were suffering from cardiovascular diseases in 2021, and 375,476 people died with cardiovascular diseases that same year. Therefore, the prevalence of cardiovascular diseases will drive the atherosclerosis drug market.

Get A Free Sample Of The Report (Includes Graphs And Tables):

https://www.thebusinessresearchcompany.com/sample.aspx?id=12621&type=smp

The atherosclerosis drugs market covered in this report is segmented –

1) By Drug Class: Anti-Platelet Medications, Fibric Acid And Omega-3 Fatty Acid Derivatives, Angiotensin-Covering Enzyme (ACE) Inhibitors, Diuretics, Cholesterol Lowering Medication, Beta Blockers, Calcium Channel Blockers, Other Drug Classes

2) By Route Of Administration: Oral, Injectable

3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Other Distribution Channels

Product innovation is a key trend gaining popularity in the atherosclerosis drugs market going forward. Major companies operating in the atherosclerosis drugs market are developing innovative drugs and getting approvals to sustain their position in the market. For instance, in December 2021, Novartis AG, a Switzerland-based pharmaceutical company, received the US Food and Drug Administration (FDA) approval for Leqvio (inclisiran), a first-of-its-kind siRNA to lower cholesterol and treat people with atherosclerotic cardiovascular disease. This new drug is in the form of subcutaneous injection and reduces the amount of LDL (low-density lipoproteins) cholesterol in the bloodstream for the treatment of adults with clinical atherosclerotic cardiovascular disease. It provides a new option for patients who are not able to achieve their LDL cholesterol goals with other therapies.

The atherosclerosis drugs market report table of contents includes: